{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:42:19Z","timestamp":1788172939132,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T00:00:00Z","timestamp":1483056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology , Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/01\/IYBA\/2009, BT\/MED\/30\/SP11273\/2015; BT\/PR8764\/MED\/97\/104\/2013"],"award-info":[{"award-number":["BT\/01\/IYBA\/2009, BT\/MED\/30\/SP11273\/2015; BT\/PR8764\/MED\/97\/104\/2013"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SB\/SO\/BB\/013\/2013"],"award-info":[{"award-number":["SB\/SO\/BB\/013\/2013"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13402-016-0308-2","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T09:45:08Z","timestamp":1483091108000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K\/AKT pathway activation"],"prefix":"10.1007","volume":"40","author":[{"given":"Suresh","family":"Bugide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Gonugunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudevarao","family":"Penugurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Lakshmi","family":"Malisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna K.","family":"Vadlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bramanandam","family":"Manavathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,30]]},"reference":[{"key":"308_CR1","first-page":"186","volume":"18","author":"RP Perez","year":"1991","unstructured":"R.P. Perez, A.K. Godwin, T.C. Hamilton, R.F. Ozols, Ovarian cancer biology. Semin Oncol 18, 186\u2013204 (1991)","journal-title":"Semin Oncol"},{"key":"308_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"K.R. Cho, M. Shih Ie, Ovarian cancer. Ann Rev Pathol 4, 287\u2013313 (2009). doi: 10.1146\/annurev.pathol.4.110807.092246","journal-title":"Ann Rev Pathol"},{"key":"308_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2583","volume":"9","author":"TA Yap","year":"2009","unstructured":"T.A. Yap, C.P. Carden, S.B. Kaye, Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9, 167\u2013181 (2009). doi: 10.1038\/nrc2583","journal-title":"Nat Rev Cancer"},{"key":"308_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60","author":"N Colombo","year":"2006","unstructured":"N. Colombo, T. Van Gorp, G. Parma, F. Amant, G. Gatta, C. Sessa, I. Vergote, Ovarian cancer. Crit Rev Oncol Hematol 60, 159\u2013179 (2006). doi: 10.1016\/j.critrevonc.2006.03.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"308_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13402-015-0235-7","volume":"38","author":"S Patel","year":"2015","unstructured":"S. Patel, L. Kumar, N. Singh, Metformin and epithelial ovarian cancer therapeutics. Cell Oncol 38, 365\u2013375 (2015). doi: 10.1007\/s13402-015-0235-7","journal-title":"Cell Oncol"},{"key":"308_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13402-015-0251-7","volume":"39","author":"M Zou","year":"2016","unstructured":"M. Zou, X. Zhang, C. Xu, IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells. Cell Oncol 39, 47\u201357 (2016). doi: 10.1007\/s13402-015-0251-7","journal-title":"Cell Oncol"},{"key":"308_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"R.C. Bast Jr., B. Hennessy, G.B. Mills, The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415\u2013428 (2009). doi: 10.1038\/nrc2644","journal-title":"Nat Rev Cancer"},{"key":"308_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"H. Naora, D.J. Montell, Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5, 355\u2013366 (2005). doi: 10.1038\/nrc1611","journal-title":"Nat Rev Cancer"},{"key":"308_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13402-016-0289-1","volume":"39","author":"J Mikula-Pietrasik","year":"2016","unstructured":"J. Mikula-Pietrasik, P. Uruski, K. Matuszkiewicz, S. Szubert, R. Moszynski, D. Szpurek, S. Sajdak, A. Tykarski, K. Ksiazek, Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol 39, 473\u2013481 (2016). doi: 10.1007\/s13402-016-0289-1","journal-title":"Cell Oncol"},{"key":"308_CR10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1111\/j.1349-7006.2008.00946.x","volume":"99","author":"Y Kuwabara","year":"2008","unstructured":"Y. Kuwabara, T. Yamada, K. Yamazaki, W.L. Du, K. Banno, D. Aoki, M. Sakamoto, Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci 99, 1933\u20131939 (2008). doi: 10.1111\/j.1349-7006.2008.00946.x","journal-title":"Cancer Sci"},{"key":"308_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2009.09.017","volume":"291","author":"D Vergara","year":"2010","unstructured":"D. Vergara, B. Merlot, J.P. Lucot, P. Collinet, D. Vinatier, I. Fournier, M. Salzet, Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291, 59\u201366 (2010). doi: 10.1016\/j.canlet.2009.09.017","journal-title":"Cancer Lett"},{"key":"308_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","volume":"4","author":"BT Hennessy","year":"2005","unstructured":"B.T. Hennessy, D.L. Smith, P.T. Ram, Y. Lu, G.B. Mills, Exploiting the PI3K\/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988\u20131004 (2005). doi: 10.1038\/nrd1902","journal-title":"Nat Rev Drug Discov"},{"key":"308_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489\u2013501 (2002). doi: 10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"key":"308_CR14","doi-asserted-by":"publisher","first-page":"15981","DOI":"10.1073\/pnas.0607445103","volume":"103","author":"B Manavathi","year":"2006","unstructured":"B. Manavathi, F. Acconcia, S.K. Rayala, R. Kumar, An inherent role of microtubule network in the action of nuclear receptor. Proc Natl Acad Sci U S A 103, 15981\u201315986 (2006). doi: 10.1073\/pnas.0607445103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"308_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1172\/JCI64265","volume":"123","author":"X Xu","year":"2013","unstructured":"X. Xu, Z. Fan, L. Kang, J. Han, C. Jiang, X. Zheng, Z. Zhu, H. Jiao, J. Lin, K. Jiang, L. Ding, H. Zhang, L. Cheng, H. Fu, Y. Song, Y. Jiang, J. Liu, R. Wang, N. Du, Q. Ye, Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 123, 630\u2013645 (2013). doi: 10.1172\/JCI64265","journal-title":"J Clin Invest"},{"key":"308_CR16","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1038\/onc.2014.389","volume":"34","author":"S Bugide","year":"2015","unstructured":"S. Bugide, D. David, A. Nair, N. Kannan, V.S. Samanthapudi, J. Prabhakar, B. Manavathi, Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics. Oncogene 34, 4601\u20134612 (2015). doi: 10.1038\/onc.2014.389","journal-title":"Oncogene"},{"key":"308_CR17","doi-asserted-by":"publisher","first-page":"9429","DOI":"10.1038\/srep09429","volume":"5","author":"Y Feng","year":"2015","unstructured":"Y. Feng, X. Xu, Y. Zhang, J. Ding, Y. Wang, X. Zhang, Z. Wu, L. Kang, Y. Liang, L. Zhou, S. Song, K. Zhao, Q. Ye, HPIP is upregulated in colorectal cancer and regulates colorectal cancer cell proliferation, apoptosis and invasion. Sci Rep 5, 9429 (2015). doi: 10.1038\/srep09429","journal-title":"Sci Rep"},{"key":"308_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/cas.12754","volume":"106","author":"Y Feng","year":"2015","unstructured":"Y. Feng, L. Li, X. Zhang, Y. Zhang, Y. Liang, J. Lv, Z. Fan, J. Guo, T. Hong, B. Ji, Q. Ji, G. Mei, L. Ding, S. Zhang, X. Xu, Q. Ye, HPIP is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, migration and invasion. Cancer Sci 106, 1313\u20131322 (2015). doi: 10.1111\/cas.12754","journal-title":"Cancer Sci"},{"key":"308_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biopha.2015.12.012","volume":"77","author":"J Pan","year":"2016","unstructured":"J. Pan, Y. Qin, M. Zhang, HPIP promotes non-small cell lung cancer cell proliferation, migration and invasion through regulation of the sonic hedgehog signaling pathway. Biomed Pharmacother\u00a077, 176\u2013181 (2016). doi: 10.1016\/j.biopha.2015.12.012","journal-title":"Biomed. Pharmacother."},{"key":"308_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/jop.12210","volume":"44","author":"S Okada","year":"2015","unstructured":"S. Okada, T. Irie, J. Tanaka, R. Yasuhara, G. Yamamoto, T. Isobe, C. Hokazono, T. Tachikawa, Y. Kohno, K. Mishima, Potential role of hematopoietic pre-B-cell leukemia transcription factor-interacting protein in oral carcinogenesis. J Oral Pathol Med 44, 115\u2013125 (2015). doi: 10.1111\/jop.12210","journal-title":"J Oral Pathol Med"},{"key":"308_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biopha.2015.08.027","volume":"75","author":"SC Wang","year":"2015","unstructured":"S.C. Wang, D.S. Chai, C.B. Chen, Z.Y. Wang, L. Wang, HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K\/AKT signaling pathway. Biomed Pharmacother 75, 33\u201339 (2015). doi: 10.1016\/j.biopha.2015.08.027","journal-title":"Biomed Pharmacother"},{"key":"308_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/neuonc\/not308","volume":"16","author":"DG Vuurden van","year":"2014","unstructured":"D.G. van Vuurden, E. Aronica, E. Hulleman, L.E. Wedekind, D. Biesmans, A. Malekzadeh, M. Bugiani, D. Geerts, D.P. Noske, W.P. Vandertop, G.J. Kaspers, J. Cloos, T. Wurdinger, P.P. van der Stoop, Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology 16, 946\u2013959 (2014). doi: 10.1093\/neuonc\/not308","journal-title":"Neuro-Oncology"},{"key":"308_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/cdd.2014.2","volume":"21","author":"K Shostak","year":"2014","unstructured":"K. Shostak, F. Patrascu, S.I. Goktuna, P. Close, L. Borgs, L. Nguyen, F. Olivier, A. Rammal, H. Brinkhaus, M. Bentires-Alj, J.C. Marine, A. Chariot, MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation. Cell Death Differ 21, 811\u2013824 (2014). doi: 10.1038\/cdd.2014.2","journal-title":"Cell Death Differ"},{"key":"308_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1042\/BCJ20160019","volume":"473","author":"VN Gajulapalli","year":"2016","unstructured":"V.N. Gajulapalli, V.S. Samanthapudi, M. Pulaganti, S.S. Khumukcham, V.L. Malisetty, L. Guruprasad, S.K. Chitta, B. Manavathi, A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells. Biochem J 473, 1047\u20131061 (2016). doi: 10.1042\/BCJ20160019","journal-title":"Biochem J"},{"key":"308_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.18632\/oncotarget.725","volume":"4","author":"GR Sareddy","year":"2013","unstructured":"G.R. Sareddy, B.C. Nair, S.K. Krishnan, V.K. Gonugunta, Q.G. Zhang, T. Suzuki, N. Miyata, A.J. Brenner, D.W. Brann, R.K. Vadlamudi, KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 4, 18\u201328 (2013). doi: 10.18632\/oncotarget.725","journal-title":"Oncotarget"},{"key":"308_CR26","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","volume":"68","author":"T Bonome","year":"2008","unstructured":"T. Bonome, D.A. Levine, J. Shih, M. Randonovich, C.A. Pise-Masison, F. Bogomolniy, L. Ozbun, J. Brady, J.C. Barrett, J. Boyd, M.J. Birrer, A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68, 5478\u20135486 (2008). doi: 10.1158\/0008-5472.CAN-07-6595","journal-title":"Cancer Res"},{"key":"308_CR27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420\u20131428 (2009). doi: 10.1172\/JCI39104","journal-title":"J Clin Invest"},{"key":"308_CR28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"C.L. Chaffer, R.A. Weinberg, A perspective on cancer cell metastasis. Science 331, 1559\u20131564 (2011). doi: 10.1126\/science.1203543","journal-title":"Science"},{"key":"308_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/35000034","volume":"2","author":"E Batlle","year":"2000","unstructured":"E. Batlle, E. Sancho, C. Franci, D. Dominguez, M. Monfar, J. Baulida, A. Garcia De Herreros, The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84\u201389 (2000). doi: 10.1038\/35000034","journal-title":"Nat Cell Biol"},{"key":"308_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"J.P. Thiery, H. Acloque, R.Y. Huang, M.A. Nieto, Epithelial-mesenchymal transitions in development and disease. Cell 139, 871\u2013890 (2009). doi: 10.1016\/j.cell.2009.11.007","journal-title":"Cell"},{"key":"308_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/ncb1173","volume":"6","author":"BP Zhou","year":"2004","unstructured":"B.P. Zhou, J. Deng, W. Xia, J. Xu, Y.M. Li, M. Gunduz, M.C. Hung, Dual regulation of snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931\u2013940 (2004). doi: 10.1038\/ncb1173","journal-title":"Nat Cell Biol"},{"key":"308_CR32","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995). doi: 10.1038\/378785a0","journal-title":"Nature"},{"key":"308_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/35000025","volume":"2","author":"A Cano","year":"2000","unstructured":"A. Cano, M.A. Perez-Moreno, I. Rodrigo, A. Locascio, M.J. Blanco, M.G. del Barrio, F. Portillo, M.A. Nieto, The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76\u201383 (2000). doi: 10.1038\/35000025","journal-title":"Nat Cell Biol"},{"key":"308_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","volume":"97","author":"S Lee","year":"2005","unstructured":"S. Lee, E.J. Choi, C. Jin, D.H. Kim, Activation of PI3K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97, 26\u201334 (2005). doi: 10.1016\/j.ygyno.2004.11.051","journal-title":"Gynecol Oncol"},{"key":"308_CR35","first-page":"89","volume":"37","author":"H Asechi","year":"2010","unstructured":"H. Asechi, E. Hatano, T. Nitta, M. Tada, K. Iwaisako, N. Tamaki, H. Nagata, M. Narita, A. Yanagida, I. Ikai, S. Uemoto, Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 37, 89\u201396 (2010)","journal-title":"Int J Oncol"},{"key":"308_CR36","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"E. Lengyel, Ovarian cancer development and metastasis. Am J Pathol 177, 1053\u20131064 (2010). doi: 10.2353\/ajpath.2010.100105","journal-title":"Am J Pathol"},{"key":"308_CR37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"R.J. Kurman, M. Shih Ie, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 42, 918\u2013931 (2011). doi: 10.1016\/j.humpath.2011.03.003","journal-title":"Hum Pathol"},{"key":"308_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1006\/gyno.2000.5805","volume":"78","author":"JL Brun","year":"2000","unstructured":"J.L. Brun, A. Feyler, G. Chene, J. Saurel, G. Brun, C. Hocke, Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78, 21\u201327 (2000). doi: 10.1006\/gyno.2000.5805","journal-title":"Gynecol Oncol"},{"key":"308_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1172\/JCI65833","volume":"123","author":"RG Verhaak","year":"2013","unstructured":"R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, S. Fereday, M. Lawrence, S.L. Carter, C.H. Mermel, A.D. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, K. Levanon, C. Sougnez, A. Tsherniak, S. Gomez, R. Onofrio, S. Gabriel, L. Chin, N. Zhang, P.T. Spellman, Y. Zhang, R. Akbani, K.A. Hoadley, A. Kahn, M. Kobel, D. Huntsman, R.A. Soslow, A. Defazio, M.J. Birrer, J.W. Gray, J.N. Weinstein, D.D. Bowtell, R. Drapkin, J.P. Mesirov, G. Getz, D.A. Levine, M. Meyerson, Cancer genome atlas research, Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123, 517\u2013525 (2013). doi: 10.1172\/JCI65833","journal-title":"J Clin Invest"},{"key":"308_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9","author":"M Osaki","year":"2004","unstructured":"M. Osaki, M. Oshimura, H. Ito, PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667\u2013676 (2004). doi: 10.1023\/B:APPT.0000045801.15585.dd","journal-title":"Apoptosis"},{"key":"308_CR41","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, A.K. Godwin, J.R. Testa, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853\u20135857 (2004). doi: 10.1038\/sj.onc.1207721","journal-title":"Oncogene"},{"key":"308_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2159-8290.CD-11-0170","volume":"2","author":"AJ Hanrahan","year":"2012","unstructured":"A.J. Hanrahan, N. Schultz, M.L. Westfal, R.A. Sakr, D.D. Giri, S. Scarperi, M. Janakiraman, N. Olvera, E.V. Stevens, Q.B. She, C. Aghajanian, T.A. King, E. Stanchina, D.R. Spriggs, A. Heguy, B.S. Taylor, C. Sander, N. Rosen, D.A. Levine, D.B. Solit, Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2, 56\u201367 (2012). doi: 10.1158\/2159-8290.CD-11-0170","journal-title":"Cancer Discov"},{"key":"308_CR43","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0002-9440(10)64681-0","volume":"158","author":"K Kurose","year":"2001","unstructured":"K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, C. Eng, Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158, 2097\u20132106 (2001). doi: 10.1016\/S0002-9440(10)64681-0","journal-title":"Am J Pathol"},{"key":"308_CR44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9440(10)61714-2","volume":"159","author":"M Sun","year":"2001","unstructured":"M. Sun, G. Wang, J.E. Paciga, R.I. Feldman, Z.Q. Yuan, X.L. Ma, S.A. Shelley, R. Jove, P.N. Tsichlis, S.V. Nicosia, J.Q. Cheng, AKT1\/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159, 431\u2013437 (2001)","journal-title":"Am J Pathol"},{"key":"308_CR45","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.onc.1203598","volume":"19","author":"ZQ Yuan","year":"2000","unstructured":"Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, C. Jiang, D. Coppola, S.V. Nicosia, J.Q. Cheng, Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase\/Akt pathway in human ovarian cancer. Oncogene 19, 2324\u20132330 (2000). doi: 10.1038\/sj.onc.1203598","journal-title":"Oncogene"},{"key":"308_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, J.W. Gray, PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99\u2013102 (1999). doi: 10.1038\/5042","journal-title":"Nat Genet"},{"key":"308_CR47","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1016\/j.ejca.2013.08.007","volume":"49","author":"KE Sheppard","year":"2013","unstructured":"K.E. Sheppard, C. Cullinane, K.M. Hannan, M. Wall, J. Chan, F. Barber, J. Foo, D. Cameron, A. Neilsen, P. Ng, J. Ellul, M. Kleinschmidt, K.M. Kinross, D.D. Bowtell, J.G. Christensen, R.J. Hicks, R.W. Johnstone, G.A. McArthur, R.D. Hannan, W.A. Phillips, R.B. Pearson, Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K\/mTOR and RAS\/ERK pathway inhibitors. Eur J Cancer 49, 3936\u20133944 (2013). doi: 10.1016\/j.ejca.2013.08.007","journal-title":"Eur J Cancer"},{"key":"308_CR48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"N Cancer","year":"2011","unstructured":"N. Cancer, Genome atlas research, integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011). doi: 10.1038\/nature10166","journal-title":"Nature"},{"key":"308_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2407-9-111","volume":"9","author":"V Auner","year":"2009","unstructured":"V. Auner, G. Kriegshauser, D. Tong, R. Horvat, A. Reinthaller, A. Mustea, R. Zeillinger, KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9, 111 (2009). doi: 10.1186\/1471-2407-9-111","journal-title":"BMC Cancer"},{"key":"308_CR50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"G. Singer, R. Oldt 3rd, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, M. Shih Ie, Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484\u2013486 (2003)","journal-title":"J Natl Cancer Inst"},{"key":"308_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000101307","volume":"185","author":"A Bagnato","year":"2007","unstructured":"A. Bagnato, L. Rosano, Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185, 85\u201394 (2007). doi: 10.1159\/000101307","journal-title":"Cells Tissues Organs"},{"key":"308_CR52","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1097\/IGC.0000000000000279","volume":"24","author":"Y Yang","year":"2014","unstructured":"Y. Yang, J. Zhang, Y. Zhu, Z. Zhang, H. Sun, Y. Feng, Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K\/Akt-snail signaling pathway. Int J Gynecol Cancer 24, 1564\u20131574 (2014). doi: 10.1097\/IGC.0000000000000279","journal-title":"Int J Gynecol Cancer"},{"key":"308_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3727\/096504016X14575597858654","volume":"24","author":"GY Zhang","year":"2016","unstructured":"G.Y. Zhang, A.H. Liu, G.M. Li, J.R. Wang, HPIP silencing prevents epithelial-mesenchymal transition induced by TGF-beta1 in human ovarian cancer cells. Oncol Res 24, 33\u201339 (2016). doi: 10.3727\/096504016X14575597858654","journal-title":"Oncol Res"},{"key":"308_CR54","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo, G. Kroemer, Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883 (2012). doi: 10.1038\/onc.2011.384","journal-title":"Oncogene"},{"key":"308_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fonc.2013.00251","volume":"3","author":"J Chien","year":"2013","unstructured":"J. Chien, R. Kuang, C. Landen, V. Shridhar, Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 3, 251 (2013). doi: 10.3389\/fonc.2013.00251","journal-title":"Front Oncol"},{"key":"308_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4149\/304_150806N433","volume":"63","author":"Y Zhang","year":"2016","unstructured":"Y. Zhang, C. Bao, Q. Mu, J. Chen, J. Wang, Y. Mi, A.J. Sayari, Y. Chen, M. Guo, Reversal of cisplatin resistance by inhibiting PI3K\/Akt signal pathway in human lung cancer cells. Neoplasma 63, 362\u2013370 (2016). doi: 10.4149\/304_150806N433","journal-title":"Neoplasma"},{"key":"308_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3892\/or.2016.4827","volume":"36","author":"CF Hu","year":"2016","unstructured":"C.F. Hu, Y.Y. Huang, Y.J. Wang, F.G. Gao, Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells. Oncol Rep 36, 455\u2013461 (2016). doi: 10.3892\/or.2016.4827","journal-title":"Oncol Rep"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-016-0308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-016-0308-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-016-0308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:04:17Z","timestamp":1498359857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-016-0308-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,30]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s13402-016-0308-2","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,30]]}}}